News|Articles|August 25, 2026

Report: Postpartum depression market expected to grow based on awareness, pipeline progress

Fact checked by: Benjamin P. Saylor

With brexanolone withdrawn in 2025, zuranolone leads PPD treatment as luvesilocin and LPCN 1154 advance in trials.

The postpartum depression (PPD) treatment market is expected to grow through 2036 across the 7 major markets—the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan—according to a market analysis published by DelveInsight Business Research, LLP. In 2025, the total diagnosed prevalent cases of maternal PPD across these markets were approximately 1.3 million, a figure projected to rise over the forecast period.1